Dulaglutide
Trulicity
- Made by
- Eli Lilly
- FDA approval
- September 2014
- Indication
- Type 2 diabetes
- Dose ceiling
- 4.5 mg weekly
- Typical loss
- ~3–4% body weight at 6–12 months at 4.5 mg
- Cash list
- $890–$1,000 list
Both are GLP-1 receptor agonists. Beyond that they differ in molecule, FDA indication, dose ceiling, and — most importantly to most people reading this — what the scale actually does over the long run.
Dulaglutide
Semaglutide
Both once-weekly GLP-1s for type 2 diabetes. Trulicity (dulaglutide) has a gentler autoinjector experience but generally produces less weight loss and smaller A1c reduction than Ozempic at maximum doses. Trulicity wins on injection comfort; Ozempic wins on raw efficacy.
Molecule
TrulicityDulaglutide
OzempicSemaglutide
Receptor(s)
TrulicityGLP-1
OzempicGLP-1
Manufacturer
TrulicityEli Lilly
OzempicNovo Nordisk
FDA approval
TrulicitySeptember 2014
OzempicDecember 2017
Indication
TrulicityType 2 diabetes
OzempicType 2 diabetes (with later cardiovascular and CKD indications)
Delivery
TrulicitySubcutaneous injection, once weekly
OzempicSubcutaneous injection, once weekly
Dose ceiling
Trulicity4.5 mg weekly
Ozempic2.0 mg weekly
Titration
TrulicityMaintenance from 0.75 mg; titration optional
Ozempic4 weeks per step
Typical loss
Trulicity~3–4% body weight at 6–12 months at 4.5 mg
Ozempic~6% body weight at 6–12 months in T2D patients; ~10–13% in non-diabetic off-label use at higher doses
Cash list
Trulicity$890–$1,000 list
Ozempic$950–$1,350
On patent until
Trulicity2027 (with composition extensions)
Ozempic2031 (US composition of matter)
No journeys yet — be the first.